BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) following successful Phase 3 trial results. The drug demonstrated rapid and sustained normalization of calcium metabolism in patients and a favorable safety profile. With a "Buy" rating from analysts and a $101.00 price target, encaleret is poised to be the first approved therapy for ADH1, with potential for expansion into pediatric ADH1 and chronic hypoparathyroidism.

Birkenstock (BIRK) stock dropped 12.9% following its fiscal Q2 results, which reported revenue of €618 million and significant gross margin pressure. The decline in gross margin to 53.9% was mainly due to unfavorable FX translation, incremental U.S. tariffs, and channel mix, despite growth across regions. Investors reacted to the near-term profitability hit, even though the company reaffirmed its full-year targets.

Bionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).

William H. Gates III and Cascade Investment, L.L.C. recently acquired over half a million shares of Republic Services, Inc. (NYSE:RSG) for approximately $100.5 million. These purchases occurred between May 11 and May 13, 2026, with share prices ranging from $197.18 to $203.6701, bringing their collective holdings to over 110 million shares. The waste management company, a 10% owner of which is held by Gates and Cascade, has a market cap of $62.6 billion and a 1.23% dividend yield.

This article provides a comprehensive overview of Coincheck Group N.V.'s (CNCK) SEC filings, including 10-K, 10-Q, and 8-K forms, as tracked by StockTitan. It details recent filings such as KDDI's strategic investment, monthly trading metrics, and insider transactions related to RSU vesting for various executives. The content highlights financial results for fiscal year 2026, where total revenue increased and net loss narrowed, and provides details on company data, rankings, and a list of available tools and articles on the StockTitan platform.

Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.

Argan Inc (AGX) shares rose 5.7% to $719.92, significantly above its GF Value™ of $139.31, indicating it is approximately 416.8% overvalued. Despite a GF Score™ of 81/100, reflecting strong fundamentals in financial strength, profitability, and growth, its valuation and momentum rankings are low. Insiders have sold $39.1 million worth of shares in the last three months, suggesting a lack of confidence in the current stock price.

Andrew M. Schleimer, CFO of TKO Group Holdings (NASDAQ:TKO), recently acquired 2,696 shares of Class A Common Stock for approximately $499,953, with prices ranging from $184.99 to $186.21 per share. These purchases were made to fulfill an obligation under Section 16(b) of the Securities Exchange Act of 1934, matching prior sales made in January 2026. The company currently has a "GOOD" financial health rating and a PEG ratio of 0.48, suggesting it is undervalued according to InvestingPro.

A lawsuit deadline is approaching on May 18, 2026, for investors in Gartner, Inc. (NYSE: IT) concerning alleged securities law violations. The lawsuit claims that Gartner made misleading statements regarding its contract value growth and Consulting segment revenue outlook between February 4, 2025, and February 2, 2026, leading to a significant drop in stock price. Investors who purchased shares during this period are encouraged to contact the Shareholders Foundation.

Director William Carson purchased 8,000 shares of Annexon Inc (ANNX) on May 11, 2026, bringing his total holdings to 78,405 shares. This recent acquisition is part of a broader trend where Carson has bought 52,805 shares over the past year without any sales. On the day of the transaction, Annexon Inc shares were trading at $5.78, with a market capitalization of $892.941 million.